IF a dual-AAV2/7 system co-delivering (i) a phospho-site-deficient ASCL1 variant (ASCL1-6SA; serine/threonine-to-alanine substitutions at CDK5/GSK3β consensus sites, under gfaABC1D promoter, 1×10¹² vg/ml) together with (ii) CasRx-mediated dual knockdown of NFIA and NFIB (the NFI-family glial identity maintainers, under gfaABC1D promoter, 2×10¹² vg/ml) and (iii) a third AAV2/7 encoding LMX1A–T2A–NURR1 under the same promoter (1×10¹² vg/ml; total 4 μl co-injected at AP −3.1 mm, ML ±1.2 mm, DV −4.6 mm from bregma) is delivered stereotaxically to the substantia nigra pars compacta (SNc) of 8–10-week-old male Aldh1l1-CreERT2;Rosa26-tdTomato C57BL/6 mice at 1 week post-6-OHDA lesion (tamoxifen induction 2 weeks pre-lesion),
THEN at 16 weeks post-injection, ≥15% of tdTomato⁺ astrocyte-lineage cells in the SNc will be tdTomato⁺/TH⁺/NeuN⁺ triple-positive, striatal dopamine content (HPLC-ECD) will be restored to ≥40% of the intact contralateral hemisphere, and amphetamine-induced rotational asymmetry will be reduced by ≥50% relative to lesion-only vehicle controls,
BECAUSE three mechanistically independent and sequentially necessary barriers to astrocyte-to-dopaminergic-neuron conversion are jointly dismantled:
- Wild-type ASCL1 pioneer activity is suppressed by CDK5/GSK3β phosphorylation in mature astrocytes, preventing chromatin remodeling at neuronal loci. The phospho-site-deficient ASCL1-6SA variant retains full bHLH DNA binding while escaping kinase-mediated inhibition, enabling it to open silent neuronal chromatin in post-mitotic astrocytes in a mann





























